Pacira BioSciences (PCRX) News Today $22.36 +0.30 (+1.36%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRXJanuary 17 at 10:50 PM | prnewswire.comPCRX Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Pacira BioSciences, Inc.January 17 at 5:29 PM | globenewswire.comLowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmJanuary 17 at 11:46 AM | globenewswire.comZacks Research Has Positive Outlook of PCRX FY2024 EarningsPacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Investment analysts at Zacks Research upped their FY2024 earnings estimates for shares of Pacira BioSciences in a research note issued on Tuesday, January 14th. Zacks Research analyst R. Department now anticipates that the company will post eJanuary 17 at 6:40 AM | marketbeat.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit - PCRXJanuary 17 at 5:45 AM | prnewswire.comPCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law FirmJanuary 17 at 3:27 AM | prnewswire.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PaciraJanuary 16 at 8:15 PM | stockhouse.comPCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 16 at 4:00 PM | prnewswire.comInvestors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights – PCRXJanuary 16 at 1:56 PM | globenewswire.comPacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights - PCRXJanuary 16 at 5:45 AM | prnewswire.comRoyal Bank of Canada Reaffirms "Sector Perform" Rating for Pacira BioSciences (NASDAQ:PCRX)January 16 at 3:51 AM | americanbankingnews.comPACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRXJanuary 15 at 11:01 PM | globenewswire.comThe Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming DeadlineJanuary 15 at 12:47 PM | globenewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRXJanuary 15 at 12:45 PM | globenewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PaciraJanuary 15 at 11:22 AM | prnewswire.comPCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud LawsuitJanuary 15 at 1:46 AM | prnewswire.comStockholder Notice: Robbins LLP Informs Stockholders of the Pacira BioSciences, Inc. Class Action LawsuitJanuary 14 at 8:03 PM | prnewswire.comPCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 14 at 4:00 PM | globenewswire.comPCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law FirmJanuary 14 at 2:06 PM | businesswire.comPacira BioSciences' (PCRX) Sector Perform Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reissued a "sector perform" rating and issued a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday.January 14 at 12:08 PM | marketbeat.comSHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Pacira BioSciences, Inc. (PCRX) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the FirmJanuary 14 at 12:05 PM | globenewswire.comGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Pacira BioSciences, Inc. (PCRX)January 14 at 11:35 AM | globenewswire.comPacira BioSciences (NASDAQ:PCRX) Stock Price Expected to Rise, Needham & Company LLC Analyst SaysJanuary 14 at 3:03 AM | americanbankingnews.comRosen Law Firm Urges Pacira BioSciences, Inc. (NASDAQ: PCRX) Stockholders with Large Losses to Contact the Firm for Information About Their RightsJanuary 13, 2025 | businesswire.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Pacira BioSciences, Inc. Securities and Sets a Lead Plaintiff Deadline of March 14, 2025January 13, 2025 | globenewswire.comPacira Pharmaceuticals: Strong Growth Prospects and Strategic Goals Drive Buy RatingJanuary 13, 2025 | markets.businessinsider.comTruist Financial Remains a Sell on Pacira Pharmaceuticals (PCRX)January 13, 2025 | markets.businessinsider.comNeedham & Company LLC Boosts Pacira BioSciences (NASDAQ:PCRX) Price Target to $30.00Needham & Company LLC upped their target price on shares of Pacira BioSciences from $22.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday.January 13, 2025 | marketbeat.comPacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical OrganizationJanuary 10, 2025 | markets.businessinsider.comPacira BioSciences (NASDAQ:PCRX) Shares Gap Up - What's Next?Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up - Should You Buy?January 10, 2025 | marketbeat.comPacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve BlockJanuary 7, 2025 | markets.businessinsider.comPacira BioSciences, Inc. (NASDAQ:PCRX) Insider Jonathan Slonin Sells 879 SharesPacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) insider Jonathan Slonin sold 879 shares of Pacira BioSciences stock in a transaction on Monday, January 6th. The stock was sold at an average price of $18.40, for a total transaction of $16,173.60. Following the completion of the sale, the insider now owns 93,444 shares of the company's stock, valued at approximately $1,719,369.60. This trade represents a 0.93 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.January 6, 2025 | marketbeat.comPacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | globenewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from BrokeragesPacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has received a consensus rating of "Hold" from the ten ratings firms that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have givDecember 25, 2024 | marketbeat.comState Street Corp Boosts Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)State Street Corp raised its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 5.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,014,012 shares of the company's stoDecember 22, 2024 | marketbeat.comWellington Management Group LLP Sells 32,486 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Wellington Management Group LLP lowered its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 6.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 454,649 shares of the company's stock after sellDecember 17, 2024 | marketbeat.comFmr LLC Cuts Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Fmr LLC decreased its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 97.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 67,165 shares of the company's stock after selDecember 17, 2024 | marketbeat.comShareholder Rights Advocates at Levi & Korsinsky Investigate Pacira BioSciences, Inc. (PCRX) Regarding Possible Securities Fraud ViolationsDecember 16, 2024 | markets.businessinsider.comJanus Henderson Group PLC Cuts Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)Janus Henderson Group PLC reduced its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 96.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,319 shares of the company's stoDecember 16, 2024 | marketbeat.comFY2024 EPS Forecast for Pacira BioSciences Raised by AnalystPacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Stock analysts at Zacks Research boosted their FY2024 EPS estimates for shares of Pacira BioSciences in a note issued to investors on Wednesday, December 11th. Zacks Research analyst R. Department now expects that the company will earn $2.60December 16, 2024 | marketbeat.comQ1 EPS Estimate for Pacira BioSciences Lowered by AnalystPacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Analysts at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for Pacira BioSciences in a research note issued on Wednesday, December 11th. Zacks Research analyst R. Department now forecasts that the company will earn $0.60December 13, 2024 | marketbeat.comVerition Fund Management LLC Makes New $493,000 Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)Verition Fund Management LLC purchased a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 32,788 shares of the company's stock, valued at approxDecember 12, 2024 | marketbeat.comDOMA Perpetual Capital to nominate four candidates to Pacira’s boardDecember 12, 2024 | markets.businessinsider.comDOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.December 11, 2024 | prnewswire.comCentiva Capital LP Acquires Shares of 26,473 Pacira BioSciences, Inc. (NASDAQ:PCRX)Centiva Capital LP acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 26,473 shares of the company's stock, valued at approximatelyDecember 10, 2024 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)December 6, 2024 | globenewswire.comDecoding 6 Analyst Evaluations For Pacira BioSciencesDecember 4, 2024 | benzinga.comBNP Paribas Financial Markets Increases Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)BNP Paribas Financial Markets increased its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 269.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 395,695 shares of the company's stock aftDecember 4, 2024 | marketbeat.comPacira Awarded New U.S. Patent Covering EXPAREL CompositionDecember 3, 2024 | globenewswire.comQ4 EPS Forecast for Pacira BioSciences Reduced by AnalystPacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Equities researchers at Zacks Research dropped their Q4 2024 earnings per share (EPS) estimates for shares of Pacira BioSciences in a research report issued to clients and investors on Wednesday, November 27th. Zacks Research analyst R. DeparDecember 2, 2024 | marketbeat.com Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address PCRX Media Mentions By Week PCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCRX News Sentiment▼0.210.72▲Average Medical News Sentiment PCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCRX Articles This Week▼305▲PCRX Articles Average Week Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Perrigo News Today Supernus Pharmaceuticals News Today Omeros News Today Nektar Therapeutics News Today Assembly Biosciences News Today Cumberland Pharmaceuticals News Today Eli Lilly and Company News Today Johnson & Johnson News Today AbbVie News Today Merck & Co., Inc. News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCRX) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
